5,358 reports of this reaction
3.4% of all RIBAVIRIN reports
#4 most reported adverse reaction
RASH is the #4 most commonly reported adverse reaction for RIBAVIRIN, manufactured by Bausch Health US, LLC. There are 5,358 FDA adverse event reports linking RIBAVIRIN to RASH. This represents approximately 3.4% of all 157,291 adverse event reports for this drug.
RIBAVIRIN has an overall safety score of 85 out of 100. Patients taking RIBAVIRIN who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is moderately reported among RIBAVIRIN users, representing a notable but not dominant share of adverse events.
In addition to rash, the following adverse reactions have been reported for RIBAVIRIN:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 5,358 FDA reports for RIBAVIRIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 3.4% of all adverse event reports for RIBAVIRIN, making it a notable side effect.
If you experience rash while taking RIBAVIRIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.